A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.
Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Check each source note before turning a row into a claim.
This page links out to registry/source records, the global trial tracker, the updates feed, and the matching wiki dossier.
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: RECRUITING | Exact phase: Not listed | Lead sponsor: University of California, Irvine | Conditions: Opioid Use Disorder (OUD)
ClinicalTrials.gov manual QA on 2026-04-17 | Exact registry status: Withdrawn | Official title: Trifecta Research Study: Examining Hormone Replacement Therapy, Magnetic e-Resonance Therapy, Ibogaine, and 5-MeO-DMT in the Treatment of Posttraumatic Stress Disorder and Traumatic Brain Injury-related Cognitive Symptoms | Sponsor: Johns Hopkins University | Conditions: PTSD - Post Traumatic Stress Disorder; Cognitive Dysfunction; Brain Trauma; Brain Injuries | Interventions: Hormone Replacement Therapy (HRT); Magnetic Resonance Therapy (MeRT); ibogaine with magnesium treatment; 5-MeO-DMT | Study type: Interventional
ClinicalTrials.gov manual QA on 2026-04-17 | Status: Completed | Sponsor: International Center for Ethnobotanical Education, Research, and Service | Official title: Preliminar Efficacy and Safety of Ibogaine in the Treatment of Methadone | Condition: Opioid Dependence | Intervention: Ibogaine Hydrochloride | Study type: Interventional
ClinicalTrials.gov manual QA on 2026-04-17 | Exact registry status: Active, not recruiting | Official title: A Pre-post Study Evaluating the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Sequelae of Repeated Blast Exposure | Sponsor: Stanford University | Conditions: Blast or Combat Exposure; Head Injury Trauma | Intervention: ibogaine with magnesium treatment | Study type: Observational
ClinicalTrials.gov manual QA on 2026-04-17 | Exact registry status: Completed | Official title: Tolerability and Efficacy of Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial | Sponsor: University of Sao Paulo | Condition: Alcoholism | Intervention: Ibogaine Hydrochloride | Study type: Interventional
ClinicalTrials.gov v2 sync on 2026-04-10 | Overall status: COMPLETED | Exact phase: Phase 1, Phase 2 | Lead sponsor: atai Therapeutics, Inc. | Conditions: Opiate Withdrawal Syndrome
Last checked: 2026-05-17 07:00 UTC. FDA EO/CNPV page still names voucher indications — psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD — but does not name the psilocybin/MDD company. Claim boundary: regulatory-process/indication list only; not approval, not safety/effectiveness finding, not label/access/reimbursement, and not primary confirmation of the psilocybin/MDD sponsor.
FDA page excerpt in direct scrape: national priority vouchers to companies studying psilocybin for TRD, psilocybin for MDD, methylone for PTSD; no company named for psilocybin/MDD in checked text.
PubMed PMID 42129626 reports that single-dose ibogaine in adult mice restored juvenile-like experience-dependent plasticity in visual cortex after monocular deprivation and was accompanied by changes in perineuronal nets, parvalbumin staining, and inhibitory synaptic markers.
Last checked 2026-05-15 UTC. Claim boundary: preclinical mouse neuroplasticity study only; not human addiction, depression, PTSD, Parkinson's, clinical efficacy, broad safety, approval, label, reimbursement, or access evidence.